We has been advancing the development of the FLD® series, which enables contactless and non-invasive measurement of various indicators (biomarkers), including more advanced metrics such as HbA1c, not just oxygen saturation. The development is focused on two main axes: multi-architecture and simultaneous multi-item measurement.
Based on this development plan, we have successfully developed the function for measuring “HbA1c,” a diabetes indicator, on both iPhone (iOS) and Android versions, and have now reached the practical application stage. Further details are scheduled to be announced and released gradually in 2024.